• Topas and Lilly sign deal to focus on immune tolerance pharmaceutical-technology
    August 24, 2017
    German biotechnology company Topas Therapeutics has signed a multi-year agreement with Eli Lilly and Company to jointly work on antigen-specific tolerance induction, with an initial focus on external antigens thought to induce inflammation and / or autoim
PharmaSources Customer Service